30 research outputs found
A single-arm, open-label study to assess the immunogenicity, safety, and efficacy of etanercept manufactured using the serum-free, high-capacity manufacturing process administered to patients with rheumatoid arthritis
Objective: To evaluate the immunogenicity, safety, and efficacy of etanercept (ETN) manufactured
using the serum-free, high-capacity manufacturing (SFHCM) process in patients with rheumatoid
arthritis (RA).
----- Methods: In this global, multicenter, open-label, single-arm study (NCT02378506), 187 adult patients
with moderate to severe RA received ETN 50 mg once weekly for 24 weeks manufactured using the
SFHCM process. Immunogenicity (presence of antidrug antibodies (ADAs) and neutralizing antibodies
(NAbs)) was assessed at 12 and 24 weeks. Safety and efficacy were evaluated at 4, 12, and 24 weeks.
----- Results: Eight (4.5%) patients tested positive for ADA, and there were no NAbs detected at any time
throughout the study. Ninety (48.1%) patients reported treatment-emergent adverse events (AEs), of
which 27 (14.4%) reported injection-site reactions, and 43 (23.0%) reported infections. The majority of
AEs were mild or moderate in severity, and the drug was well tolerated. Throughout the duration of
the study (week 4 to week 24), there was a progressive increase in the American College of Rheumatology
(ACR)-defined responses (ACR20: 55.9%–82.0%, ACR50: 16.1%–57.8%, and ACR70: 3.2%–26.7%)
from baseline and the proportion of patients achieving low disease activity and remission, with a
corresponding decrease in measures of disease activity.
----- Conclusion: The immunogenicity, safety, and efficacy of ETN manufactured using the SFHCM process
were similar to the current approved ETN formulation. ClinicalTrials.gov registration: NCT02378506
Excretion of Moxidectin into Breast Milk and Pharmacokinetics in Healthy Lactating Women â–¿ â€
Moxidectin, registered worldwide as a veterinary antiparasitic agent, is currently under development for humans for the treatment of onchocerciasis in collaboration with the World Health Organization. The objective of this study was to assess the pharmacokinetics of moxidectin in healthy lactating women, including the excretion into breast milk. Twelve women, ages 23 to 38 years, weighing 54 to 79 kg, all more than 5 months postpartum, were enrolled, following their plan to wean their infants and provision of informed consent. A single 8-mg, open-label dose was administered orally after consumption of a standard breakfast. Complete milk collection was done for approximately 28 days, and plasma samples were collected for 90 days. Moxidectin concentrations were measured by high-performance liquid chromatography (HPLC) with fluorescence detection, with a validated range of 0.08 to 120 ng/ml. Noncompartmental pharmacokinetic methods were used to find the following results: peak concentration in plasma (Cmax), 87 ± 25 ng/ml; time to Cmax (tmax), 4.18 ± 1.59 h; terminal-phase elimination half-life (t1/2), 832 ± 321 h; total area under the concentration-time curve (AUC), 4,046 ± 1,796 ng·h/ml; apparent oral dose clearance (CL/F), 2.35 ± 1.07 l/h; ratio of CL/F to the terminal-phase disposition rate constant, λz
(Vλz/F), 2,526 ± 772 liters; percentage of maternal dose excreted in milk, 0.701 ± 0.299%; absolute amount excreted in milk, 0.056 ± 0.024 mg; relative infant dose, 8.73 ± 3.17% of maternal dose assuming complete absorption; clearance in milk (CLmilk), 0.016 ± 0.009 liter/h. Nine of 12 subjects reported adverse events, all of which were considered treatment emergent but not drug related and were mostly reported during the long outpatient period 8 to 90 days after dose administration. The most frequently reported adverse events were headache and nausea (n = 4), oropharyngeal pain (n = 2), rhinitis, viral pharyngitis, and viral upper respiratory tract infection (n = 2)
Once-Weekly Prophylactic Treatment Versus on-Demand Treatment of Nonacog Alfa in Patients with Moderately Severe to Severe Hemophilia B
56th Annual Meeting of the American-Society-of-Hematology -- DEC 06-09, 2014 -- San Francisco, CAWOS: 000349233806027Amer Soc Hemato